Harm reduction in tobacco control: where do we draw the line?
Study Goal
The researchers aimed to evaluate the safety and efficacy of chewing tobacco as a harm reduction alternative for smoking cessation.
Results Summary
The study found inconclusive results regarding the effectiveness of chewing tobacco for quitting smoking, with evidence of continued use and additional health risks not present in traditional tobacco smoking. Public health efforts should focus on safer alternatives like nicotine replacement therapy.
Population
Not specified (general substance abuse/tobacco users).
Effective Dosage
Not mentioned
Duration
Not mentioned
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
chewing tobacco | no change | quit smoking | - | inconclusive results | inconclusive results | #1 |
e-cigarettes | no change | quit smoking | - | inconclusive results | inconclusive results | #2 |
chewing tobacco | no change | use of these agents | - | continued use | demonstrated continued use | #3 |
e-cigarettes | no change | use of these agents | - | continued use | demonstrated continued use | #4 |
many smoking harm reduction agents | increase | health risks | - | other health risks | pose other health risks | #5 |
With substance abuse, harm reduction refers to reducing or replacing use of a harmful product with a less risky agent. But many advertised "non-pharmaceutical" harm reduction alternatives for tobacco smoking are problematic. Studies have revealed inconclusive results using agents including chewing tobacco and e-cigarettes to quit smoking and have demonstrated continued use of these agents. Many smoking harm reduction agents pose other health risks not found in traditional tobacco smoking. Given these limitations, efforts should focus on promoting nicotine replacement therapy, and other pharmacologic agents with a better chance of producing sustained smoking cessation. To address the harmful nature of many tobacco replacement products, public health should focus on regulating these alternatives with the same stringency as tobacco, and social marketing efforts should target evidence-based and safer pharmaceutical grade or behavioural alternatives.